Inventiva Valuation Multiples

Inventiva Overview

About Inventiva

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Founded

2011

HQ

Employees

119

Website

inventivapharma.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $5M

EBITDA: ($157M)

EV

$958M

Valuation Multiples

Multiples.vc

Start free trial

Inventiva Financials

Inventiva reported last 12-month revenue of $5M and negative EBITDA of ($157M).

In the same LTM period, Inventiva generated $5M in gross profit, ($157M) in EBITDA losses, and had net loss of ($336M).

Inventiva P&L

In the most recent fiscal year, Inventiva reported revenue of $5M and EBITDA of ($161M).

Inventiva expects next 12-month revenue of XXX and NTM EBITDA of XXX

Inventiva Stock Performance

Inventiva has current market cap of $1B, and enterprise value of $958M.

Inventiva's stock price is $5.59.

Inventiva Valuation Multiples

Inventiva trades at 195.6x EV/Revenue multiple, and (6.1x) EV/EBITDA.

Inventiva Financial Valuation Multiples

As of April 19, 2026, Inventiva has market cap of $1B and EV of $958M.

Equity research analysts estimate Inventiva's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Inventiva has a P/E ratio of (3.5x).

Inventiva Margins & Growth Rates

Inventiva's revenue in the last 12 month grew by 120%.

Inventiva's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.4M for the same period.

Inventiva's rule of 40 is (3534%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Inventiva's rule of X is (3563%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Inventiva Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Inventiva M&A Activity

Inventiva acquired XXX companies to date.

Last acquisition by Inventiva was on XXXXXXXX, XXXXX. Inventiva acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Inventiva Investment Activity

Inventiva invested in XXX companies to date.

Inventiva made its latest investment on XXXXXXXX, XXXXX. Inventiva invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).